IRIS
CAROTENUTO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.001
NA - Nord America 4.550
EU - Europa 3.944
SA - Sud America 718
AF - Africa 161
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.345
SG - Singapore 2.501
RU - Federazione Russa 1.637
CN - Cina 1.223
VN - Vietnam 1.088
IT - Italia 903
BR - Brasile 543
HK - Hong Kong 503
DE - Germania 398
FR - Francia 204
NL - Olanda 190
IN - India 144
GB - Regno Unito 125
CA - Canada 119
JP - Giappone 112
FI - Finlandia 107
KR - Corea 86
IE - Irlanda 83
UA - Ucraina 74
AR - Argentina 65
BD - Bangladesh 58
ZA - Sudafrica 53
MX - Messico 45
CI - Costa d'Avorio 38
ES - Italia 37
PH - Filippine 36
PL - Polonia 36
SE - Svezia 36
TH - Thailandia 35
IQ - Iraq 33
EC - Ecuador 30
TR - Turchia 26
AT - Austria 23
ID - Indonesia 23
VE - Venezuela 20
CO - Colombia 19
LT - Lituania 19
PK - Pakistan 18
TW - Taiwan 16
SA - Arabia Saudita 15
BE - Belgio 14
CL - Cile 13
JO - Giordania 13
MA - Marocco 12
MY - Malesia 12
TN - Tunisia 12
PY - Paraguay 11
CZ - Repubblica Ceca 10
NP - Nepal 10
AE - Emirati Arabi Uniti 9
EG - Egitto 8
KE - Kenya 8
AU - Australia 7
DZ - Algeria 7
JM - Giamaica 7
PE - Perù 7
NI - Nicaragua 6
NZ - Nuova Zelanda 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
GR - Grecia 5
IR - Iran 5
MK - Macedonia 5
PT - Portogallo 5
BG - Bulgaria 4
CR - Costa Rica 4
HR - Croazia 4
IL - Israele 4
MN - Mongolia 4
OM - Oman 4
PA - Panama 4
RS - Serbia 4
AM - Armenia 3
CU - Cuba 3
HN - Honduras 3
LV - Lettonia 3
MD - Moldavia 3
UY - Uruguay 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
GA - Gabon 2
GD - Grenada 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
QA - Qatar 2
RE - Reunion 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
Totale 15.364
Salva come PNG Salva come JPEG
Città #
Singapore 1.238
San Jose 804
Ashburn 481
Hong Kong 474
Moscow 424
Hefei 401
Beijing 330
Ho Chi Minh City 325
Chandler 309
Hanoi 250
Santa Clara 226
Naples 199
Los Angeles 158
Amsterdam 145
Lauterbourg 110
Tokyo 104
The Dalles 96
Munich 86
Millbury 77
New York 77
Dallas 75
Seoul 69
Council Bluffs 68
São Paulo 60
Des Moines 57
Buffalo 56
Boston 52
Milan 52
Da Nang 50
Napoli 50
Redondo Beach 49
Frankfurt am Main 41
Denver 40
Montreal 40
Nanjing 39
Seattle 38
Haiphong 37
Helsinki 37
Princeton 37
Lawrence 36
Krefeld 33
Rome 32
Dublin 31
Orem 31
Chicago 29
Warsaw 29
Johannesburg 28
Norwalk 28
Toronto 27
London 26
Stockholm 26
Dong Ket 24
Falkenstein 24
Turku 23
Chennai 22
Houston 22
Atlanta 21
Brooklyn 21
Nuremberg 19
Mexico City 18
Lappeenranta 17
Phoenix 17
Pune 17
Tianjin 17
Wilmington 17
Boardman 16
Rio de Janeiro 16
Biên Hòa 15
Ottawa 15
Poplar 15
Rottweil 15
Baghdad 14
Düsseldorf 14
Paris 14
Bangkok 13
Can Tho 13
Curitiba 13
Ankara 12
Belo Horizonte 12
Cava De' Tirreni 12
Thái Nguyên 12
Manchester 11
Mumbai 11
San Francisco 11
Amman 10
Bari 10
Brasília 10
Bến Tre 10
Catania 10
Hải Dương 10
Kolkata 10
Quito 10
Shanghai 10
Brussels 9
Formia 9
Nanchang 9
Turin 9
Vienna 9
Campinas 8
Cape Town 8
Totale 8.301
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 275
Uric acid: a potential biomarker of multiple sclerosis and of its disability 208
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 181
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 179
The use of medical-grade cannabis in patients non-responders to Nabiximols 167
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 167
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 164
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 164
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 160
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 160
The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study 159
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 155
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 155
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 152
Inhibition of oligodendrocyte differentiation by immunoglobulin purified from serum of multiple sclerosis patients during relapse 150
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 150
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 148
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 148
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 146
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 144
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 143
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 143
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 143
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 143
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 143
A real-world study of alemtuzumab in a cohort of Italian patients 142
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 142
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy 142
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis 141
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 141
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 141
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 140
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 140
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 139
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 139
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 138
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 138
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 138
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 137
Retinal vascular density in multiple sclerosis: a one year follow up 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 135
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 135
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 134
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 131
Exploring the relation between reserve and fatigue in multiple sclerosis 130
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 130
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis 130
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 129
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 129
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 128
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 128
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 128
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 127
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 126
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 125
Correction to: Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 125
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 124
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 124
Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition 123
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 121
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 120
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. 120
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 120
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 119
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 118
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 118
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 118
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 117
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 117
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 116
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 116
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 116
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis 114
Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data 114
Dysphagia assessment in patients with multiple sclerosis - an additional piece to disability burden 112
Anatomical and functional retinal changes in multiple sclerosis 112
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 112
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis 110
Can people with multiple sclerosis actually understand what they read in the Internet age? 110
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 110
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 109
A longitudinal real-life comparison study of natalizumab and fingolimod 108
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 108
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 108
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 108
Integration of the expanded disability status scale with ambulation, visual and cognitive tests 107
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 107
Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis 104
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 104
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 103
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 103
Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia 102
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 102
Association between CD20+ T lymphocytes and neuropsychological findings in multiple sclerosis 101
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications 98
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 98
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 95
The Framingham cardiovascular risk score in multiple sclerosis 94
Low serum 25‑hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosis 89
Prevalence and Incidence of Paramagnetic Rim Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis 89
Totale 13.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 0 33
2021/2022467 8 1 4 6 11 36 8 17 58 34 105 179
2022/20231.000 81 87 20 43 87 125 152 53 152 132 45 23
2023/2024678 32 96 84 56 41 85 17 71 21 17 101 57
2024/20254.047 182 179 32 72 132 251 432 279 246 431 1.414 397
2025/20268.642 836 743 888 908 1.474 291 884 613 1.057 631 244 73
Totale 15.762